Drugs / RO7297089
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04434469 | Jul 2020 → Feb 2022 | plasma cell myeloma | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO7297089 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04434469 ↗ |
| Route | Intravenous | “RO7297089 was administered weekly by intravenous infusion” PMID 36656461 ↗ Jan 2023 |